Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD34 molecule (Cluster of differentiation 34) (CD34)
- Target
- CD34
- Molecular classification
- Cell surface glycoprotein, Single-pass transmembrane protein, Sialomucin family, Adhesion molecule
01
Overview
CD34 is a transmembrane phosphoglycoprotein encoded by the CD34 gene. It is primarily expressed on hematopoietic stem and progenitor cells but also present on some endothelial and mesenchymal cells. Functionally, CD34 acts as an adhesion molecule mediating attachment of stem cells to bone marrow extracellular matrix and stromal cells. Its expression is crucial for stem cell migration, homing, and immune cell trafficking. Clinically, CD34 marks cells for stem cell isolation in regenerative medicine and serves as a biomarker in oncology and hematology. Ongoing research investigates its broader roles in cell migration and tissue regeneration, as well as its involvement in cancer stem cell biology.
- Other names
- CD34 antigenCluster of differentiation 34CD34 moleculeHematopoietic progenitor cell antigen
02
Mechanism of action
Cell isolation/enrichment: Antibodies bind to CD34 for isolating stem cells from blood or bone marrow; Stem cell mobilization: Drugs increase CD34+ cell counts for transplantation
03
Biological functions
Cell-cell adhesionCell-matrix interactionStem cell homing to bone marrowMigration of hematopoietic and endothelial progenitorsImmune cell traffickingFacilitates cell migration
04
Disease associations
Cancer: Used as a marker for cancer stem cells and tumor vasculatureHematological malignancy: Marker in leukemia and lymphoma diagnosticsRegenerative medicine: Essential for stem cell transplantationOther: Involved in vascular diseases and wound healing
05
Safety considerations
Overestimation of blasts: CD34+ cell counting can overcount myeloid blasts due to non-blast populationsContamination risk: Non-hematopoietic CD34+ cells may be inadvertently enriched during transplantation
06
Interacting drugs
Stem cell mobilizers (e.g., filgrastim, plerixafor) indirectly target CD34+ cells for mobilization
1 more in the full profile.
07
Biomarkers
CD34+ cell count: Used for patient selection and efficacy monitoring in hematopoietic stem cell transplantationCD34+ blast calculation: Prognostic in acute leukemia
Beyond the preview
Go deeper on CD34 molecule (Cluster of differentiation 34) (CD34).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34 molecule (Cluster of differentiation 34) (CD34).